Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tislelizumab

tislelizumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tislelizumab

36 trials tracked of tislelizumab: 10 in phase 3 or 4 and 10 with published results. The most-cited published study has 398 citations.

36Trials tracked
10Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 3 10 Phase 2 22 Phase 1 4
  1. Phase 3 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Completed · 398 cited
  2. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 305 cited
  3. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 286 cited
  4. Phase 3 A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer Completed · 274 cited
  5. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 241 cited
  6. Phase 3 Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Completed · 211 cited
Show 30 more trials
  1. Phase 3 Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 122 cited
  2. Phase 3 Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) Completed · 102 cited
  3. Phase 3 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma Completed · 68 cited
  4. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 7 cited
  5. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  6. Phase 2 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Completed
  7. Phase 2 Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Completed
  8. Phase 2 A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer Completed
  9. Phase 2 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed
  10. Phase 2 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed
  11. Phase 2 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors Completed
  12. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  13. Phase 2 Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer Completed
  14. Phase 2 Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody Completed
  15. Phase 2 Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer Completed
  16. Phase 2 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors Completed
  17. Phase 2 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer Completed
  18. Phase 2 Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Completed
  19. Phase 2 Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors Completed
  20. Phase 2 Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Completed
  21. Phase 2 A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC Completed
  22. Phase 2 Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Completed
  23. Phase 2 A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma Completed
  24. Phase 2 Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Completed
  25. Phase 2 AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer Completed
  26. Phase 2 Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma Completed
  27. Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed
  28. Phase 1 Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Completed
  29. Phase 1 A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors Completed
  30. Phase 1 Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Pulmonology & Critical Care RCT
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Jun 7, 2026
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Allergy & Immunology Meta-analysis
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Frontiers May 14, 2026
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
Oncology Meta-analysis
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1 A New Drug Sequence Shrank Lung Tumors When Others Failed
This is a case report with literature review of a 79-year-old male with MET exon 14 skipping non-small cell lung cancer and high PD-L1 expre…
A 79-year-old man's lung tumors shrank when doctors switched his drug sequence, offering a clue for others with hard-to-treat cancer.
Frontiers May 12, 2026
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
Dermatology Sys. Review
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Frontiers May 8, 2026
Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Gastroenterology Phase II
Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
May 1, 2026
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
Pulmonology & Critical Care Phase I
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
This phase I trial evaluated subcutaneous versus intravenous tislelizumab in treatment-naive patients with advanced non-small cell lung canc…
Early data suggest subcutaneous tislelizumab injections may offer similar drug levels to intravenous forms for treating advanced lung cancer…
May 1, 2026
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Oncology Cohort
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Frontiers Apr 30, 2026
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Oncology RCT
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma.
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Apr 28, 2026
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Oncology Cohort
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Frontiers Apr 28, 2026
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma
Rheumatology Cohort
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Frontiers Apr 14, 2026
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Pulmonology & Critical Care Phase II
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Apr 6, 2026

All tislelizumab Articles